Tesaro Inc. (TSRO) PT Raised to $120.00 at Robert W. Baird
Tesaro Inc. (NASDAQ:TSRO) had its price target upped by analysts at Robert W. Baird to $120.00 in a research note issued to investors on Monday. Robert W. Baird’s target price indicates a potential upside of 20.89% from the company’s current price.
Several other equities analysts also recently commented on TSRO. Zacks Investment Research downgraded shares of Tesaro from a “hold” rating to a “sell” rating in a research report on Wednesday, June 15th. FBR & Co increased their target price on shares of Tesaro from $65.00 to $93.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 29th. Jefferies Group downgraded Tesaro from a “buy” rating to a “hold” rating and raised their price target for the company from $53.00 to $75.00 in a research report on Thursday, June 30th. They noted that the move was a valuation call. Leerink Swann raised their price target on Tesaro from $65.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, June 30th. Finally, Mizuho reaffirmed an “outperform” rating and issued a $67.00 price target on shares of Tesaro in a research report on Thursday, June 30th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $102.69.
Shares of Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. The stock’s 50 day moving average price is $96.42 and its 200-day moving average price is $68.96. Tesaro has a 12 month low of $29.51 and a 12 month high of $110.48. The firm’s market capitalization is $5.10 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/tesaro-inc-tsro-pt-raised-to-120-00-at-robert-w-baird.html
Tesaro (NASDAQ:TSRO) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. The firm had revenue of $36.60 million for the quarter, compared to the consensus estimate of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same period in the prior year, the business posted ($1.51) earnings per share. On average, equities analysts anticipate that Tesaro will post ($7.36) earnings per share for the current fiscal year.
In related news, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total value of $2,509,442.64. Following the completion of the transaction, the vice president now owns 29,166 shares in the company, valued at approximately $2,509,442.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total transaction of $44,112.96. Following the completion of the transaction, the senior vice president now owns 1,250 shares of the company’s stock, valued at approximately $135,150. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of TSRO. IFP Advisors Inc boosted its position in Tesaro by 109.6% in the second quarter. IFP Advisors Inc now owns 4,208 shares of the biopharmaceutical company’s stock valued at $354,000 after buying an additional 2,200 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Tesaro by 24.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 107,043 shares of the biopharmaceutical company’s stock worth $8,997,000 after buying an additional 20,750 shares in the last quarter. Amalgamated Bank acquired a new stake in Tesaro during the second quarter worth approximately $260,000. Metropolitan Life Insurance Co. NY raised its stake in Tesaro by 3.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 19,006 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 637 shares in the last quarter. Finally, Highbridge Capital Management LLC acquired a new stake in Tesaro during the second quarter worth approximately $3,584,000. Hedge funds and other institutional investors own 88.81% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.